Compared with BRCA1-deficient tumors, BRCA2-deficient tumors have a greater abundance of genes expressing innate and acquired immunity and a greater population of macrophages, natural killer cells, T cells, and dendritic cells in the tumor microenvironment. The gene discussed is BRCA2; the disease is neoplasm.